Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

BACKGROUND: Intrinsic or acquired resistance to HER2-targeted therapy is often a problem when small molecule tyrosine kinase inhibitors or antibodies are used to treat patients with HER2 positive breast cancer. Therefore, the identification of new targets and therapies for this patient group is warr...

Descripción completa

Detalles Bibliográficos
Autores principales: Keller, Magdalena, Rohlf, Katharina, Glotzbach, Annika, Leonhardt, Gregor, Lüke, Simon, Derksen, Katharina, Demirci, Özlem, Göçener, Defne, AlWahsh, Mohammad, Lambert, Jörg, Lindskog, Cecilia, Schmidt, Marcus, Brenner, Walburgis, Baumann, Matthias, Zent, Eldar, Zischinsky, Mia-Lisa, Hellwig, Birte, Madjar, Katrin, Rahnenführer, Jörg, Overbeck, Nina, Reinders, Jörg, Cadenas, Cristina, Hengstler, Jan G., Edlund, Karolina, Marchan, Rosemarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854078/
https://www.ncbi.nlm.nih.gov/pubmed/36670508
http://dx.doi.org/10.1186/s13046-022-02578-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854078/
https://www.ncbi.nlm.nih.gov/pubmed/36670508
http://dx.doi.org/10.1186/s13046-022-02578-w

Ejemplares similares